ACAD vs NBIX
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. NBIX: Neurocrine is a profitably growing, neuroscience-focused biotech commercializing novel treatments for movement disorders, endocrine diseases, and psychiatric conditions with expanding late-stage pipeline and recent M&A.
Side-by-side fundamentals
| Metric | ACAD | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.96 | $172.69 | |
| Market cap as of 2026-07-23 | $4.4B | $17.8B | |
| P/E as of 2026-07-23 | 11.59 | 26.70 | ACAD lower |
| PEG as of 2026-07-23 | -5.27 | 0.23 | ACAD lower |
| Net margin as of 2026-07-23 | +34.3% | +21.6% | ACAD higher |
| Gross margin as of 2026-07-23 | +91.5% | +98.2% | NBIX higher |
| Operating margin as of 2026-07-23 | +7.4% | +25.4% | NBIX higher |
| ROE as of 2026-07-23 | +35.6% | +21.6% | ACAD higher |
| ROA as of 2026-07-23 | +26.2% | +15.1% | ACAD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -13.6% | +28.6% | NBIX higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +24.3% | ACAD higher |
| Beta as of 2026-07-23 | 0.86 | 0.39 | |
| 1-year return as of 2026-07-22 close | +10.6% | +30.1% | NBIX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.